Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-09-05
2002-06-04
Jones, W. Gary (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C436S063000, C436S501000, C436S503000, C536S023500, C536S027400, C536S024100, C435S091100, C435S091200
Reexamination Certificate
active
06399306
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to identifying one or more genetic markers which correlate with improved success in reducing blood pressure levels in hypertensive individuals.
BACKGROUND OF THE INVENTION
Studies have shown that individuals suffering from hypertension can alleviate symptoms or otherwise improve their conditions through exercise. Unfortunately, some individuals, no matter how rigorously they exercise, are unable to improve their conditions, while others benefit to a much greater extent than predicted. These results underscore the fact that many factors contribute to an individual's well-being. Such factors include, for example, behaviors such as diet and exercise, genetic makeup, and environment. While behavior and environment can be controlled, altered or regulated, an individual's genetic makeup is essentially predetermined and set at birth. The present inventors hypothesized that upon identifying the genetic makeup of a hypertensive population and observing that some individuals of the population lower their blood pressure from a change of behavior to a much greater or lesser extent than expected, a correlation could be made between the presence or absence of certain genetic markers and success in reducing blood pressure levels.
An object of the present invention is to identify one or more genetic markers which positively correlate with improved success in reducing blood pressure levels in hypertensive individuals.
SUMMARY OF THE INVENTION
The present inventors have discovered a number of genetic markers which positively correlate with improved success in reducing blood pressure levels in hypertensive individuals, as compared with other genetic makeup at the same gene loci. Therefore, the present invention is directed to a method of reducing blood pressure levels in a subject in need of such reduction, the method comprising:
identifying a subject having an allele and/or genotype at a particular gene locus which positively correlates with improved success in reducing blood pressure levels in hypertensive individuals, as compared with other alleles and/or genotypes at the same gene locus, wherein the subject is in need of reduced blood pressure levels, and
engaging the subject in exercise training for a period of time sufficient to reduce blood pressure levels in the subject.
DETAILED DESCRIPTION OF THE INVENTION
The inventors have found that a number of genetic markers positively correlate with improved success in reducing blood pressure levels in hypertensive individuals, as compared with other genetic makeup at the same gene loci. Markers which the inventors have investigated include the lipoprotein lipase (LPL) gene PvuII and HindIII restriction sites, the angiotensin converting enzyme (ACE) gene insertion site, and the angiotensinogen M235T site.
The term “blood pressure” includes systolic blood pressure, diastolic blood pressure and mean blood pressure. A “reduction in blood pressure” may mean a reduction in systolic blood pressure and/or diastolic blood pressure and/or mean blood pressure. Such a reduction may include daytime blood pressure and/or nighttime blood pressure, or the reduction may be unrelated to time of day.
The term “single course of exercise”, as used throughout this application, means a cardiovascular exercise session of any type which is conducted during one day. An exercise session may comprise an aerobics class, treadmill training, step machine, or any other suitable cardiovascular exercise regimen. For most cases, exercise may be completed in, for example, 30 minutes to 3 hours, with optional brief rest periods of 3-15 minutes, however this amount would vary depending on the health and endurance of the subject.
The term “extensive exercise” means about 10 single courses of exercise or more, preferably at least 15, at least 20, or at least 25 single courses of exercise, over a defined period of time (“the exercise period”). The exercise period in the case of an extensive exercise protocol may be from about 30-400 days, preferably from about 50-350 days or 70-300 days.
The term “limited exercise” means about 5 single courses of exercise or less, preferably at most 3, or 1 single course of exercise, over the exercise period. The exercise period in the case of a limited exercise protocol may be about 12 days or less, preferably at most 10, at most 7, or at most 5 days. It is most preferred that the limited exercise period be at most 3 days.
The term “moderate exercise” means about 5-9 single courses of exercise, preferably about 6-8, or 7 single courses of exercise, over the exercise period. The exercise period in the case of a limited exercise protocol may be from about 5-50 days, preferably from about 5-30 days, 5-20 days, or 5-15 days.
The time between exercise periods depends on whether the exercise period is an extensive, limited or moderate exercise period. In the case of extensive exercise periods, the time between exercise periods may be from about 10-120 days or more. In the case of limited exercise periods, the time between exercise periods may be from 4-60 days or more. In the case of moderate exercise periods, the time between exercise periods may be from 6-90 days or more. The term “between exercise periods” means that time during which the subject is not in an extensive, limited or moderate exercise program.
Lipoprotein lipase (LPL) is an enzyme that catalyzes the breakdown of triglycerides in the plasma to release free fatty acids. This hydrolysis also influences the metabolism of circulating lipoproteins. LPL has also been shown to enhance the triglyceride-rich chylomicron binding to low-density lipoprotein receptor-related proteins. Thus, LPL may also be an important regulator of chylomicron metabolism. The LPL gene is located on human chromosome 8p22. It is approximately 35 kilobases long and has 10 functionally differentiated exons. Two primary polymorphic variations occur at the LPL gene locus in frequencies that are important on a population basis. These two variations are detected by PvuII and HindIII restriction sites. There are three genotypes at each site, with the alleles for both PvuII and HindIII restriction sites denoted as “+” or “−”, based on the presence or absence of a restriction site on that allele at the LPL locus with PvuII or HindIII. Thus, for both PvuII and HindIII there are three genotypes: +/+, +/− and −/−.
The present inventors have discovered that hypertensive individuals with different PvuII genotypes exhibit different degrees of success in reducing their blood pressure levels through exercise. These results could not have been predicted from initial patient screening.
The inventors have surprisingly discovered that each PvuII genotype potentially can benefit from exercise, however, the amount of exercise which produces the most benefits varies according to genotype. Specifically, the inventors have found that subjects having a “+/+” genotype for a PvuII restriction site exhibit more reduction in blood pressure levels than those with “+/−” or “−/−” genotypes, after extensive exercise. However, those subjects having “+/−” or “−/−” genotypes exhibit more reduction in blood pressure levels than those with “+/+” genotypes, after limited exercise.
Therefore, one method of reducing blood pressure levels in a subject in need of such reduction according to the invention comprises identifying a subject having a “+/+” genotype for a PvuII restriction site in a lipoprotein lipase gene, wherein the subject is in need of reduced blood pressure levels; and engaging the subject in extensive exercise training for a period of time sufficient to reduce the blood pressure levels in the subject.
Another method of reducing blood pressure levels in a subject in need of such reduction according to the invention comprises identifying a subject having at least one “−” allele or a “+/−” or “−/−” genotype for a PvuII restriction site in a lip
Brown Michael D.
Ferrell Robert E.
Hagberg James M.
Arent Fox Kintner Plotkin & Kahn
Jones W. Gary
Taylor Janell E.
University of Maryland, College Park Office of Technology Commer
LandOfFree
Genetic markers which identify individuals who decrease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetic markers which identify individuals who decrease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic markers which identify individuals who decrease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2911801